Key Highlights

● Gilead Sciences closed at $151.17 on 9 October 2026.

● Market data consensus target is $159.26, implying about 5.35% upside.

● The analyst rating consensus is Moderate Buy.

● Royal Bank of Canada raised its target from $123 to $126.

On Friday 9 October 2026, Gilead Sciences (NASDAQ:GILD), a constituent of both the S&P 500 and the Nasdaq-100, closed at $151.17. The consensus target sits moderately above the share price, and ratings lean positive. Recent broker revisions have mostly been upward.

What Is the Latest Analyst Price Target?

Market data puts the consensus price target at $159.26, based on 29 analysts with ratings in the last 12 months. That implies upside of about 5.35% from the $151.17 close. The range is wide, with a high of $180.00 and a low of $126.00. The second data set shows a very similar mean of $159.38 from 28 analysts, with a median of $164.

What Are Wall Street Analysts Saying?

Market data records 23 Buy, 6 Hold and no Sell ratings, giving a consensus rating of Moderate Buy. The second data set shows a slightly different split of 22 Buy-equivalent ratings, five Hold and one Sell. Recent named broker actions listed by market data include JPMorgan raising its target from $160 to $170 with an Overweight rating on 7 October, Truist Financial lifting its target from $150 to $158 with a Buy rating the same day, and Morgan Stanley trimming its target from $165 to $163 while keeping Overweight.

On 8 October, Royal Bank of Canada raised its target from $123 to $126 with a Sector Perform rating, and Cantor Fitzgerald reiterated Overweight with a $155 target. HSBC raised its target to $175 on 10 September. Not every broker is positive: Barclays cut its target to $145 on 29 July with an Equal Weight rating, and Leerink Partners moved to Market Perform with a $127 target on 21 July.

What Could Help the Stock Reach the Price Target?

The consensus target suggests modest room above the current price rather than a dramatic re-rating. Market data reports that the most recent quarter delivered revenue of $7.80 billion against expectations of $7.40 billion, an increase of about 10.6% year on year. Continued revenue growth that beats expectations is the type of development that could support higher forecasts. The recent target increases from JPMorgan, Truist and HSBC also show that some brokers see further potential.

What Could Prevent the Stock Reaching the Target?

The spread of targets, from $126 to $180, shows that analysts disagree about the outlook. Two of the more cautious voices, Leerink Partners and Barclays, cut their targets in July, and RBC's $126 target sits well below the current price. Pharmaceutical companies also face clinical, regulatory and drug-pricing risks. Because the consensus upside is small, even modest disappointments could leave the share price below the target.

What Should Investors Watch Next?

Between now and then, investors may wish to follow further target revisions, any new clinical or regulatory announcements and how the share price behaves relative to the $159 consensus area.

Gilead Sciences Versus Its Analyst Targets

Gilead Sciences closed at $151.17 on 9 October 2026, against a market data consensus target of $159.26. On 8 October, Royal Bank of Canada raised its target from $123 to $126 with a Sector Perform rating, and Cantor Fitzgerald reiterated Overweight with a $155 target.